Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Liraglutide.

Research draft

Liraglutide is a GLP-1 receptor agonist used in regulated diabetes and weight-management products.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Liraglutide is a GLP-1 receptor agonist used in regulated diabetes and weight-management products.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It affects glucose-dependent insulin secretion, appetite and gastric emptying.

Human research

Randomised studies support indication-specific glycaemic and weight outcomes; populations and products differ.

Preclinical & other research

Experimental incretin work supports its pharmacology.

Safety & unknowns

Gastrointestinal symptoms and pancreatic, gallbladder and contraindication warnings matter.

Regulatory status

Victoza and Saxenda have different prescription indications. Approval does not extend to every preparation.

Reported use & evidence

Research profile draft

The supplied Liraglutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds